奥沙利铂联合吡柔比星和氟尿嘧啶治疗晚期肝癌的临床疗效分析

目的观察联合化疗治疗晚期肝癌的临床疗效及安全性。方法选取我院自2009年1月至2012年10月收治的40例晚期原发性肝癌患者作为研究对象,给予奥沙利铂、吡柔比星及氟尿嘧啶联合化疗,观察临床治疗效果及毒副反应情况。结果 40例患者CR 2例,PR13例,SD 15例,PD 10例,临床总有效率为37.5%。初治9例和复治21例患者的总有效率比较无明显差异(χ2=1.052,P>0.05)。主要毒副反应包括白细胞下降13例(32.5%),贫血2例(5.0%),血小板减少5例(12.5%),恶心呕吐6例(15.0%)。结论应用奥沙利铂为主的联合化疗方案治疗晚期原发性肝癌疗效较好,毒副反应较少,对改善患者预后具有重要价值。

Clinical Analysis of Oxaliplatin combined with Pirarubicin and Fluorouracil in the Treatment of Advanced Liver Cancer

Objective To observe the combination chemotherapy in the treatment of advanced hepatocellular carcinoma clinical efficacy and safety. Methods Our hospital from January 2009 to October 2012 admitted 40 patients with advanced primary liver cancer patients as research subjects, given oxaliplatin pirarubicin Star and fluorouracit combination chemotherapy, observe the clinical therapeutic effect and toxicity side effects. Results 40 patients with CR, PR 13, SD 15, PD 10, the clinical total effective rate of 37.5%. Initial treatment of 21 patients in nine cases and retreatment total effective rate was no significant difference （x^2 = 1.052, P〉 0.05）. The major toxicities including leukopenia in 13 cases （32.5%）, anemia in 2 cases （5.0%）, thrombocytopenia （12.5%）, and nausea and vomiting in 6 cases （15.0%）. Conclusion Oxaliplatin-based chemotherapy in the treatment of advanced primary liver cancer better efficacy, less toxicity and has important value to improve the prognosis of patients.